BriaCell Therapeutics Corp. (BCTX)
After hours:
| Previous Close | 0.7088 |
| Open | 0.7300 |
| Bid | 0.6632 x 300 |
| Ask | 0.7174 x 300 |
| Day's Range | 0.6878 - 0.7350 |
| 52 Week Range | 0.4600 - 5.9700 |
| Volume | |
| Avg. Volume | 4,923,778 |
| Market Cap | 25.147M |
| Beta (5Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2900 |
| Earnings Date | Dec 12, 2024 - Dec 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
GlobeNewswireBriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical modelsNovel therapy activates both innate and adaptive immune systemsProof of concept Phase 1/2 Study of Bria-BRES™ in metastatic breast cancer currently underway PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”),
- GlobeNewswire
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with central nervous system (CNS) metastases PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company
